Richard Schilsky, M.D. - A Deep Passion for Cancer Medicine
Dec 16, 2020 ·
49m 1s
Sign up for free
Listen to this episode and many more. Enjoy the best podcasts on Spreaker!
Download and listen anywhere
Download your favorite episodes and enjoy them, wherever you are! Sign up or log in now to access offline listening.
Description
In this episode of The Onco’Zine Brief Peter Hofland talks with Richard Schilsky, M.D. Dr. Schilsky, the Chief Medical Officer and Executive Vice President of the American Society of Clinical...
show more
In this episode of The Onco’Zine Brief Peter Hofland talks with Richard Schilsky, M.D.
Dr. Schilsky, the Chief Medical Officer and Executive Vice President of the American Society of Clinical Oncology (ASCO), is an oncologist who specializes in new drug development and treatment of gastrointestinal cancers. His impressive experience and many accomplishments in both clinical medicine and clinical research, reflect his deep passion for cancer medicine.
As a highly respected leader in the field of clinical oncology, Dr. Schilsky has spent the majority of his career at the University of Chicago, where he joined the faculty in 1984.
In 2013 he joined ASCO where he launched ASCO’s first-ever prospective clinical trial, the Targeted Agent and Profiling Utilization Registry or TAPUR Study.
Dr. Schilsky also established the Center for Research & Analytics, developed a Board-approved Policy on Research Scope, set up a process to review and fulfill requests for ASCO data, built a Division of Biostatistics and Research Data Governance, and initiated ASCO’s Research Survey Pool to support surveys of ASCO members for research purposes.
Being at the forefront of cancer medicine, Dr. Schilsky also worked on developing ASCO’s CancerLinQ which helped define a real-world evidence research strategy in cancer care, recognizing early on that big data can help us to learn from every patient’s cancer experience—not just from the 3% of patients who are able to participate in clinical trials.
In February 2021 Dr. Schilsky will be retiring from his role of chief medical officer at the American Society of Clinical Oncology. In the interview today Hofland and Schilsky talk about progress made in the treatment of cancer.
About The Onco'Zine Brief
The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.
For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit: https://www.patreon.com/theoncozinebrief
For more information about cancer and cancer treatments, visit our online journal Onco'Zine at www.oncozine.com
To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.
show less
Dr. Schilsky, the Chief Medical Officer and Executive Vice President of the American Society of Clinical Oncology (ASCO), is an oncologist who specializes in new drug development and treatment of gastrointestinal cancers. His impressive experience and many accomplishments in both clinical medicine and clinical research, reflect his deep passion for cancer medicine.
As a highly respected leader in the field of clinical oncology, Dr. Schilsky has spent the majority of his career at the University of Chicago, where he joined the faculty in 1984.
In 2013 he joined ASCO where he launched ASCO’s first-ever prospective clinical trial, the Targeted Agent and Profiling Utilization Registry or TAPUR Study.
Dr. Schilsky also established the Center for Research & Analytics, developed a Board-approved Policy on Research Scope, set up a process to review and fulfill requests for ASCO data, built a Division of Biostatistics and Research Data Governance, and initiated ASCO’s Research Survey Pool to support surveys of ASCO members for research purposes.
Being at the forefront of cancer medicine, Dr. Schilsky also worked on developing ASCO’s CancerLinQ which helped define a real-world evidence research strategy in cancer care, recognizing early on that big data can help us to learn from every patient’s cancer experience—not just from the 3% of patients who are able to participate in clinical trials.
In February 2021 Dr. Schilsky will be retiring from his role of chief medical officer at the American Society of Clinical Oncology. In the interview today Hofland and Schilsky talk about progress made in the treatment of cancer.
About The Onco'Zine Brief
The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.
For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit: https://www.patreon.com/theoncozinebrief
For more information about cancer and cancer treatments, visit our online journal Onco'Zine at www.oncozine.com
To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.
Information
| Author | Peter Hofland |
| Organization | Peter Hofland |
| Website | - |
| Tags |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company
